$维立志博-B(09_老虎社区_美港股上老虎

$维立志博-B(09887)$ 这次 LBL-034Ⅱ 期首例用药，其实最核心的是给公司 TCE 技术做了次关键验证，TCE +TCE 双抗 ADC的差异化优势后面也可能继续扩大。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":473881713939056,"tweetId":"473881713939056","gmtCreate":1756725269885,"gmtModify":1756725271246,"author":{"id":4130491647501850,"idStr":"4130491647501850","authorId":4130491647501850,"authorIdStr":"4130491647501850","name":"寂寞如红酒","avatar":"https://static.tigerbbs.com/65c631d608d204ac37af91dd7acc8e0d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a> 这次 LBL-034Ⅱ 期首例用药，其实最核心的是给公司 TCE 技术做了次关键验证，TCE +TCE 双抗 ADC的差异化优势后面也可能继续扩大。</body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a> 这次 LBL-034Ⅱ 期首例用药，其实最核心的是给公司 TCE 技术做了次关键验证，TCE +TCE 双抗 ADC的差异化优势后面也可能继续扩大。</body></html>","text":"$维立志博-B(09887)$ 这次 LBL-034Ⅱ 期首例用药，其实最核心的是给公司 TCE 技术做了次关键验证，TCE +TCE 双抗 ADC的差异化优势后面也可能继续扩大。","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/473881713939056","repostId":0,"isVote":1,"tweetType":1,"viewCount":485,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["09887"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":129,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}